[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-cord-injury-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-cord-injury-acute":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,58,99,131,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100620746","upper-limb-rehabilitation-using-non-invasive-spinal-cord-stimulation-100620746",false,"NCT07361627","Upper Limb Rehabilitation Using Non-invasive Spinal Cord Stimulation","Improving Upper Limb Motor Control With Spinal Stimulation","CIME_upperlimb","Inclusion Criteria:\n\n* quadraplegic participants with a subacute spinal cord injury (sSCI), defined as the stage of spinal cord damage occurring between 1 week and 6 months post-injury, that fall within the period of at least one year post-injury\n* 16 years old or above\n* have a lesion between above T2\n* residual upper limb movement\n* have injury level according to ASIA A to D\n* hospitalized in the hospital linked with the research center at Gingras Lindsay Rehabilitation Institute of Montreal, 6300 Darlington, Montreal\n* can provide informed consent (no severe cognitive deficits by MoCA)\n* be able to follow instructions in French or English\n\nExclusion Criteria:\n\n* have a pacemaker\n* have active cancer on stimulation site or metastatic cancer\n* have unstable health conditions\n* have unhealed wound, scar or pain which makes positioning of the electrodes impossible\n* participants with specific contraindications to TMS (epilepsy, non-union cranial fracture and increased intracranial pressure) will be able to participate in the study, but will not receive TMS","ALL","16 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this RCT study is to evaluate if combining activity-based therapy (ABT) with transcutaneous spinal cord stimulation (tSCS) can improve recovery of arm and hand movement in people with cervical spinal cord injury (SCI). As secondary aims, the study will also investigate at how this combination approach affects the cortical changes in the somatosensory and motor areas of the brain, as well as in the spinal cord and whether it helps participants use their arms more in daily life.\n\nThe main questions relevant to this study are:\n\n1. Can the combination of ABT + tSCS improve motor and sensory functions of the arms and hands more than ABT alone during the sub-acute stage after SCI?\n2. Does ABT + tSCS induce neuroplasticity, that is, changes in the brain and spinal cord activity linked to motor and sensory functions?\n3. Do participants who receive ABT + tSCS report greater use of their arms in daily activities compared to those who receive ABT only?\n\nIn this study, participants will:\n\n* Receive either ABT + tSCS or ABT + sham stimulation (a low-intensity current that does not facilitate the movements)\n* Take part in 20 training sessions over 6-8 weeks (3 times per week, 45 min of active training each). During this, they will perform strengthening, task-based training, and mental imagery exercises with a therapist.\n* Complete clinical tests and neurophysiological assessments (transspinal electrical stimulation, electroencephalography and transcranial magnetic stimulation) at three time points-- at the start, after training, and one month later to measure recovery and brain activity changes.\n\nResearchers will compare the assessment outcomes across the three time points.",[27,28,29],"Spinal Cord Injury Cervical","Spinal Cord Injury, Acute","Spinal Cord Injury (Quadraplegia)",[31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Spinal cord injury","Sub-acute","Neuromodulation","transcutaneous Spinal Cord Stimulation","Activity-based therapy","Upper extremity motor score","Rehabilitation","Electroencephalography","EEG","Somatosensory evoked potential","Transcranial Magnetic Stimulation","Motor evoked potential","Clinical assessment","Neuroplasticity","NOT_YET_RECRUITING","2026-02-27",{"date":48,"type":49},"2026-03-02","ACTUAL",{"date":51,"type":21},"2026-04-01",{"date":53,"type":21},"2028-08-09",{"name":55,"class":56},"Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100580781","phase-1-a-study-to-evaluate-the-safety-of-a-delivery-device-for-administering-lctopc1-in-participants-with-spinal-cord-injury-100580781","NCT06841770","A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury","Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device (DOSED)","DOSED","Inclusion Criteria:\n\n1. Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) or sensory incomplete, traumatic SCI (ASIA Impairment Scale B)\n2. For subjects with subacute injury, International Standards for Neurological Classification of SCI (ISNCSCI) Neurological Level of Injury (NLI) from C-4 to T-10 occurring 21 to 42 days prior to LCTOPC1 injection\n3. For subjects with chronic injury, ISNCSCI NLI from C-4 to T-10 and more than 30 days without clinical improvement from last assessment, occurring 1 to 5 years prior to LCTOPC1 injection\n4. Individuals must have at least one upper extremity ISNCSCI key muscle with at least 1\u002F5 strength\n5. 18 through 65 years of age, inclusive, at time of consent\n6. Single injury with sufficient visualization of the spinal cord injury epicenter and lesion margins to enable post-injection safety monitoring\n7. Informed consent for this protocol must be provided and documented (i.e., signed ICF)\n8. Able to participate in an elective surgical procedure to inject LCTOPC1 21 days or later following SCI\n9. Female subjects of child-bearing potential must agree to the use of contraception for 1 year following LCTOPC1 injection; male subjects must agree to use contraception to prevent pregnancy in any female partners of child-bearing potential for 1 year following LCTOPC1 injection\n\nExclusion Criteria:\n\n1. SCI due to penetrating trauma\n2. Traumatic anatomical transection, laceration, or inadequate decompression of the spinal cord based on prior surgery or MRI\n3. Any concomitant injury that interferes with the performance, interpretation, or validity of neurological examinations, such as multiple spinal cord lesions, brachial\u002Flumbar plexus injury, cauda equina injury or traumatic brain injury\n4. Subjects with a cavity structure that would preclude successful transplantation, as identified on MRI, which may include septations or irregularities in tissue structure\n5. Persons with syringomyelia, defined as those with progressively enlarging cysts on T2-weighted images associated with neurological decline\n6. Inability to communicate effectively with neurological examiner such that the validity of patient data could be compromised\n7. Organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression\n8. Need for mechanical support of ventilation (ventilator, continuous positive airway pressure \\[CPAP\\], bi-level positive airway pressure \\[BiPAP\\]), excluding supplemental oxygen, at baseline\n9. History of any malignancy (except non-melanoma skin cancers). For cancers in remission for more than five years, enrollment is allowed with concurred documented approval of principal investigator, oncologist, and Sponsor's medical monitor prior to enrollment\n10. Pregnant or nursing women\n11. Subjects with an implanted spinal cord stimulator (SCS), whether temporary or permanent.","18 Years","65 Years",{"count":69,"type":21},10,[71],"PHASE1","The DOSED clinical study evaluates the safety and utility of a novel delivery device to deliver LCTOPC1, a cell therapy, to the spinal cord of patients with a spinal cord injury (SCI). LCTOPC1 is designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a goal to help improve the quality of life and restore or augment functional activity in persons suffering from a traumatic cervical or thoracic injuries.",[27,74,28,75,76],"Spinal Cord Injury Thoracic","Spinal Cord Injury","Spinal Cord Injury, Chronic",[75,64,78,79,80,81,82,83,84,85,86],"Subacute spinal cord injury","Oligodendrocyte Progenitor Cell","Chronic spinal cord injury","Stem Cell Transplant","Cervical spinal cord injury","Thoracic spinal cord injury","Paralysis","Quadriplegia","Tetraplegia","RECRUITING","2026-02-11",{"date":90,"type":49},"2026-02-12",{"date":92,"type":49},"2025-06-30",{"date":94,"type":21},"2037-06-30",{"name":96,"class":97},"Lineage Cell Therapeutics, Inc.","INDUSTRY",2,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100359838","transcutaneous-tibial-nerve-stimulation-in-acute-spinal-cord-injury-100359838","NCT03965299","Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury","Transcutaneous Tibial Nerve Stimulation in Patients With Acute Spinal Cord Injury to Prevent Neurogenic Detrusor Overactivity: A Nationwide Randomised, Sham-controlled, Double-blind Clinical Trial","TASCI","Inclusion Criteria:\n\n* Age \\>18 years\n* Patients with acute SCI (traumatic SCI and sudden onset (\\\u003C7 days) non-traumatic SCI) within 40 days after injury\n* Patients with acute SCI at cervical or thoracic level\n* Willing to take part and follow the requirements of the TASCI protocol (up to one year after SCI)\n\n  * no percutaneous tibial nerve stimulation (PTNS)\n  * no functional electrical stimulation (FES), apart from upper limb FES\n  * no electrical muscle stimulation (EMS)\n* Informed Consent\n\nExclusion Criteria:\n\n* Contraindications to the investigational product\n* DO with contractions greater than 40 cmH2O at a bladder filling volume of less than 500mL at baseline visit\n* Treatment with antimuscarinics or with mirabegron\n* Known or suspected non-adherence, drug or alcohol abuse\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant\n* Participation in another study with investigational drug or product within the 30 days preceding and during the present study\n* Neuromodulation treatment for urological or bowel indication in the last six months or ongoing\n* Botulinum toxin injections in the detrusor and\u002For urethral sphincter in the last six months\n* Bilaterally absent tibial nerve compound muscle action potential (cMAP, amplitude \\\u003C 1mV)\n* Women who are pregnant or breast feeding\n* Intention to become pregnant during the course of the study\n* Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences \\[www.samw.ch\u002Fen\u002FNews\u002FNews.html\\])\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons\n* Pre-existing or concomitant medical condition apart from SCI that might pose a safety issue or would interfere with interpretation of study results or study conduct (e.g. Parkinson's disease, neurodegenerative disorders including multiple sclerosis and amyotrophic lateral sclerosis, urological malignancies)",{"count":108,"type":21},114,[24],"Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure. We urgently need an intervention that prevents NLUTD before irreversible damage occurs. Neuromodulation procedures are a promising avenue so that we investigate the effect of transcutaneous tibial nerve stimulation (TTNS) in patients with acute SCI.\n\nThis nationwide randomized, sham-controlled, double-blind multicentre clinical trial includes all SCI centres in Switzerland (Basel, Nottwil, Sion, Zürich). Patients are randomly assigned to VERUM TTNS (active stimulation, n=57) and SHAM stimulation (n=57) groups in a 1:1 allocation using computer-generated permuted block randomisation lists stratified on study centre and lower extremity motor score. Daily 30-minute sessions are performed five times a week during an intervention period of 6-9 weeks. The primary outcome of this study is the success of TTNS to prevent neurogenic DO jeopardizing the upper urinary tract, assessed by urodynamics at 1 year after SCI or any earlier time point if DO treatment is necessary (study end). Secondary outcome measures are bladder diary parameters, clinical symptom scores assessed by standardized and validated questionnaires. Furthermore, neurophysiological and neuroimaging outcome measures are assessed as well as, biochemical and molecular changes. Tertiary outcome measure is the safety of TTNS.\n\nBefore the actual start of the TASCI RCT, start-up activities will include a piloting phase on groups of healthy volunteers and patients. The goal during this phase is to evaluate the feasibility of the experimental setup, in particular for the TTNS and SHAM intervention, but also to test the setup of the different pre and post assessments (e.g. neurophysiology and neuroimaging tests). Groups of up to 15 participants each will be enrolled in a few consecutive pilot studies allowing for fine tuning and small adaptations in between, if appropriate.",[28],[113,114,115,116,117,118,119,120],"randomized, sham-controlled, double-blind trial","transcutaneous tibial nerve stimulation","spinal cord injury","neurogenic detrusor overactivity","neuromodulation","electrical stimulation","paraplegia; tetraplegia","urodynamics","2026-01-15",{"date":123,"type":49},"2026-01-20",{"date":125,"type":49},"2019-06-19",{"date":127,"type":21},"2026-09-30",{"name":129,"class":56},"University of Zurich",4,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100285135","systemic-hypothermia-in-acute-cervical-spinal-cord-injury-100285135","NCT02991690","Systemic Hypothermia in Acute Cervical Spinal Cord Injury","Systemic Hypothermia in Acute Cervical Spinal Cord Injury - A Prospective, Multi-center Case Controlled Study","Inclusion Criteria:\n\n* 18 - 70 years of age\n* AIS Grade A - C\n* Glasgow Coma Scale ≥14\n* Able to start hypothermia treatment within 24 hours of injury\n* Non-penetrating injury. Patients urgently taken to the operating room for surgical reduction may also be included.\n\nExclusion Criteria:\n\n* Age \\> 70 years\n* AIS Grade D\n* Hyperthermia on admission (\\>38.5ºC)\n* Severe systemic injury\n* Severe bleeding\n* Pregnancy\n* Coagulopathy\n* Thrombocytopenia\n* Known prior severe cardiac history\n* Blood dyscrasia\n* Pancreatitis\n* Reynaud's syndrome\n* Cord transection","70 Years",{"count":140,"type":21},120,[24],"This study is a prospective multi-center trial designed to determine the safety profile and efficacy of modest (33ºC) intravascular hypothermia following acute cervical (C1 to C8) Spinal Cord Injury (SCI).",[28],[145,146,147],"Hypothermia","Cervical Spinal Cord Injury","Trauma","2025-11-20",{"date":150,"type":49},"2025-11-21",{"date":152,"type":49},"2017-08-04",{"date":154,"type":21},"2026-09",{"name":156,"class":56},"University of Miami",7,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":98},"100424863","phase-1-safety-and-exploratory-efficacy-of-transplantation-therapy-using-psa-ncam-npc-in-ais-a-level-of-sub-acute-sci-100424863","NCT04812431","Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI","A Single Center, Open Label, Single Group, Phase 1\u002F2a Clinical Study to Evaluate the Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC Derived From hESC Line in AIS-A Level of Sub-acute SCI(From 7 to 60 Days)","SB-SCI-001","Inclusion Criteria:\n\n1. Upon written consent of the patient or the legally acceptable representative of the patient\n2. Male and female patients 18 to 65 years of age\n3. Female patients who showed negative results on the pregnancy test, use an acceptable contraceptive or have no possibility of pregnancy (at least 2 years have elapsed after menopause or have undergone hysterectomy, ovariectomy, or sterilization operation), or male patients who have received vasectomy or are willing to use contraceptives for up to 90 days after administration of the investigational product using a dual contraceptive method\\*\n\n   \\*Dual contraceptive method: Method of using multiple contraceptives, such as using a cervical cap or contraceptive diaphragm in addition to a condom for males\n4. Patients who are capable of being administered with the investigational product on Day 7 to 60 after spinal cord injury\n5. Patients who have been confirmed to have spinal cord injury classified as AIS-A on ISNCSCI, SCIM and\u002For MRI by the investigator, physiatrist, or other spinal cord injury specialist\n6. Patients whose ASIA Impairment Scale (AIS) satisfies AIS-A criteria (spinal segment within C4-C7, complete injury)\n\nExclusion Criteria:\n\n1. Patients with spinal cord injury caused by penetrating trauma such as gunshot or stab wounds\n2. Patients with complete transection on the spinal cord\n3. Patients with spinal cord injury that require more than the mono-segment treatment\n4. Patients with other complications, including neurological defects related to peripheral nerve injury (neuromuscular injury or central spinal cord syndrome), or etiological causes of paraplegia or sensorimotor defects related to an additional underlying condition\n5. Patients with multiple lesions or lesions longer than 2 cm in length found on MRI examination\n6. Patients administered with cells excluding blood transfusion before participating in the clinical study\n7. Patients with the following intercurrent diseases or conditions:\n\n   1. Coagulopathy with INR\\> 1.4 at the time of administration of the investigational product (Day 0)\n   2. Active infection\n   3. Active hypotension requiring vasoconstrictor treatment (less than 60 mmHg of diastolic blood pressure)\n   4. Rupture of the skin on the area of surgery\n   5. Medical history of malignant tumor\n   6. Primary or secondary immunodeficiency\n   7. Clinically significant abnormal values discovered as a result of laboratory tests\n\n      * Creatinine \\> 1.5 mg\u002FdL\n      * When the level found in the liver-function examination is more than twice the upper limit of the normal level\n      * Hematocrit\u002Fhemoglobin \\\u003C30%\u002F10 g\u002FdL\n      * Total WBC \\\u003C 1000\u002FμL\n      * Uncontrolled hypertension (systole\\> 180 mmHg or diastole\\> 100 mmHg)\n      * Uncontrolled diabetes (HbA1c\\> 8%)\n      * Evidence of GI bleeding on the stool guaiac test\n      * Positive on tuberculosis test (However, a chest X-ray may be performed if found positive on the TB test, and the patient may be enrolled upon no findings that suggest active tuberculosis on the chest X-ray.)\n      * Hepatitis B or C\n      * Human Immunodeficiency Virus (HIV)\n   8. Substance abuse or alcoholism\n   9. Unstable or untreated psychiatric disorder\n8. Patients with known hypersensitivity to basiliximab, tacrolimus, mycophenolate mofetil, methylprednisolone, or prednisone\n9. Patients incapable of receiving physical therapy or combination therapy\n10. Patients incapable of going under general anesthesia due to other reasons\n11. Patients judged unsuitable for participation in this clinical study by the investigator",{"count":5,"type":21},[71,168],"PHASE2","This study intends to evaluate the safety and exploratory efficacy of transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line for the treatment of paralysis and other related symptoms from sub-acute spinal cord injury.",[28,171,172],"Spinal Cord Injury at C4 Level With Complete Lesion","Spinal Cord Injury at C5-C7 Level With Complete Lesion",[31,174],"AIS-A","2025-05-14",{"date":177,"type":49},"2025-05-18",{"date":179,"type":49},"2021-09-23",{"date":181,"type":21},"2030-09",{"name":183,"class":97},"S.Biomedics Co., Ltd."]